In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-*39, are predictors of impending diabetes with distinct HLA-DQ interactions

Diabetologia

Volumn 56, Issue 9, 2013, Pages 1964-1970

  Mbunwe, E ^a   Van Der Auwera, B J ^a   Weets, I ^a,b   Van Crombrugge, P ^c   Crenier, L ^d   Coeckelberghs, M ^e   Seret, N ^f   Decochez, K ^a,b   Vandemeulebroucke, E ^a,b   Gillard, P ^g   Keymeulen, B ^a,b   Van Schravendijk, C ^a   Wenzlau, J M ^h   Hutton, J C ^h   Pipeleers, D G ^a   Gorus, F K ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c OLV HOSPITAL   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e Paola Kinderziekenhuis ^*  (Belgium)

^f Clinique Saint Joseph   (Belgium)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Autoantibodies; HLA class I; HLA class II; HLA A; HLA B; HLA DQ; Prediction; Prevention; Risk assessment; Type 1 diabetes

Indexed keywords

ANTIGEN; AUTOANTIBODY; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; ISLET ANTIGEN 2; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8;

ADULT; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIRST DEGREE RELATIVE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HLA A GENE; HLA B GENE; HLA DQ GENE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HLA-A24 ANTIGEN; HLA-B18 ANTIGEN; HLA-B39 ANTIGEN; HLA-DQ ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; MALE; RISK ASSESSMENT; YOUNG ADULT;

EID: 84881614925     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2951-8     Document Type: Article

References (20)

1. Mbunwe E, van der Auwera BJ, Vermeulen I et al (2013) HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients. Diabetes 62:1345-1350
2. von Herrath M, Peakman M, Roep B (2013) Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 172:186-202
3. Tait BD, Colman PG, Morahan G et al (2003) HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens 61:146-153
4. Lipponen K, Gombos Z, Kiviniemi M et al (2010) Effect of HLA class I and class II alleles on progression from autoantibody positivity to overt type 1 diabetes in children with risk-associated class II genotypes. Diabetes 59:3253-3256
5. Nejentsev S, Howson JM, Walker NM et al (2007) Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450:887-892
6. Fennessy M, Metcalfe K, Hitman GA et al (1994) A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Diabetologia 37:937-944
7. Valdes AM, Wapelhorst B, Concannon P, Erlich HA, Thomson G, Noble JA (2005) Extended DR3-D6S273-HLA-B haplotypes are associated with increased susceptibility to type 1 diabetes in US Caucasians. Tissue Antigens 65:115-119
8. Vermeulen I, Weets I, Costa O et al (2012) An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age. Diabetologia 55:413-420
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
10. Middleton D (2000) PCR-SSOP class I and class II (DRBI). In: Hahn AB, Land GA, Strothman RM (eds), ASHI laboratory manual, 4th edition. American Society for Histocompatibility and Immunogenetics, Lenexa, p. V.C.2.1-23
11. Greenbaum CJ, Buckingham B, Chase HP, Krischer J (2011) Metabolic tests to determine risk for type 1 diabetes in clinical trials. Diabetes Metab Res Rev 27:584-589
12. Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP (2012) Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 35:1975-1980
13. Honeyman MC, Harrison LC, Drummond B, Colman PG, Tait BD (1995) Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol Med 1:576-582
14. Valdes AM, Erlich HA, Noble JA (2005) Human leukocyte antigen class I B and C loci contribute to type 1 diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol 66:301-313
15. Kronenberg D, Knight RR, Estorninho M et al (2012) Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 61:1752-1759
16. Marron MP, Graser RT, Chapman HD, Serreze DV (2002) Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Natl Acad Sci U S A 99:13753-13758
17. van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79-118
18. Vandemeulebroucke E, Keymeulen B, Decochez K et al (2010) Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 53:36-44
19. Long AE, Gillespie KM, Aitken RJ, Goode JC, Bingley PJ, Williams AJ (2013) Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. Diabetes. doi: 10.2337/db12-1468
20. Nakanishi K, Kobayashi T, Murase T, Naruse T, Nose Y, Inoko H (1999) Human leukocyte antigen-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of beta-cell destruction. J Clin Endocrinol Metab 84:3721-3725